Clinical Research Directory

Inclusion Criteria: * Initial treatment with platinum-containing or taxane-based CTX (regardless of the the length of the CTX cycle) * Senological, gynecological or internistic tumors * Phantogeusia (on average ≥4 NRS) * Willingness to participate in the study and written informed consent Exclusion Criteria: * Severe stomatitis * Dysgeusia before the CTX based on neurological diseases, diabetes, or the ingestion of drugs with taste disorders as side effects * Leucopenia/neutropenia * Intake of anticoagulants * Smoking * Severe physical or mental comorbidity (due to which the patient is unable to participate in the study) * Participation in other CAM treatments within the integrative oncology care * Participation in other studies on the effectiveness of interventions for oral complications